Meropenem pharmacokinetics during relapsing peritonitis due to ESBL-producing Enterobacteriaciae in a liver transplant recipient

Kensuke Shoji; Jumpei Saito; Yusuke Oho; Shotaro Matsumoto; Satoshi Aoki; Akinari Fukuda; Seisuke Sakamoto; Mureo Kasahara; Edmund Capparelli; Isao Miyairi

doi:10.1002/ccr3.2398

Meropenem pharmacokinetics during relapsing peritonitis due to ESBL-producing Enterobacteriaciae in a liver transplant recipient

Clin Case Rep. 2019 Sep 30;7(11):2169-2173. doi: 10.1002/ccr3.2398. eCollection 2019 Nov.

Authors

Affiliations

¹ Division of Infectious Diseases Department of Medical Subspecialties National Center for Child Health and Development Tokyo Japan.
² Department of Pharmacy National Center for Child Health and Development Tokyo Japan.
³ Division of Critical Care Medicine National Center for Child Health and Development Tokyo Japan.
⁴ Organ Transplantation Center National Center for Child Health and Development Tokyo Japan.
⁵ Division of Host-Microbe Systems and Therapeutics UC San Diego La Jolla CA USA.
⁶ Department of Microbiology, Immunology, and Biochemistry University of Tennessee Health Science Center Memphis TN USA.

Abstract

We report on an 8-year-old girl with Wilson disease who developed three episodes of peritonitis due to extended-spectrum beta-lactamase-producing Escherichia coli after liver transplantation. Massive ascites were thought to account for low meropenem concentrations with standard dosing. Extending the infusion achieved higher troughs, greater time above minimum inhibitory concentration.

Keywords: liver transplantation; meropenem; pediatrics; pharmacokinetics; prolonged infusion.